All In Biotech

Drug Trial Radar · NCT07295834

Modafinil For Fatigue in IBD

A Multi-centre, Double-blind Randomised Controlled Trial to Compare Modafinil Versus Placebo Over 12 Weeks in Patients With Severe Fatigue and Inflammatory Bowel Disease (MFI): a Feasibility Study

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

May 5, 2026

Primary completion

Dec 1, 2027

Study completion Feb 1, 2028

Sponsor

Lead sponsor
Imperial College LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Guy's and St Thomas' NHS Foundation Trust; King's College Hospital NHS Trust; Imperial College Healthcare NHS Trust; London North West University Health Care NHS Trust
First posted
Dec 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Fatigue is a big problem in people with inflammatory bowel disease (IBD). Even when IBD is well controlled, 50% of patients remain fatigued most of the time. Fatigue can be physical (e.g. feeling tired or weak) and mental (e.g. brain fog). However, there are no effective treatments for IBD fatigue. Modafinil is a medication that can rapidly improve fatigue. It usually acts within 30 minutes and improves wakefulness. It can also improve brain fog. Modafinil has been used for over 30 years in people with narcolepsy, which is a condition where people fall asleep during the day. Modafinil has also been used in people who do not have narcolepsy. This study will compare modafinil with a dummy tablet (placebo) in people with IBD. This is a feasibility study. This means it primarily aims to test whether a trial like this can be conducted in people with IBD. Half of the patients in the study will receive modafinil and half will receive placebo. Treatment will be 12 weeks. Patients will start by taking 1 tablet and will then increase to 2 tablets and then 3 tablets if needed. A computer will randomly allocate treatment, meaning there is an equal chance of being allocated modafinil or placebo. They will be followed up after 6 weeks and 12 weeks. Being a feasibility study, the investigators will measure how many patients consent to the study; how many complete treatment; and how acceptable the treatment is. Participants will complete a range of questionnaires measuring fatigue, mental health and gut health, primarily to look at the completeness and spread of data, and to obtain estimates of treatment effects and their variance. If feasible, this study will support a larger version of the trial.

Conditions

  • Crohn Disease (CD)
  • Ulcerative Colitis (UC)
  • Fatigue

Interventions

  • ModafinilDrug

    100-300mg daily according to patient response

  • PlaceboDrug

    1-3 placebo capsules according to patient response

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recruitment rateTime frame: 2 years
  2. Trial adherenceTime frame: 12 weeks
  3. Treatment adherenceTime frame: 12 weeks
  4. Study procedures acceptability and complianceTime frame: 12 weeks
  5. Overall acceptabilityTime frame: 12 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Imperial College Healthcare NHS Trust

    London, United Kingdom · Recruiting

  • St Mark's Hospital

    London, United Kingdom · Recruiting

  • Guy's and St Thomas' NHS Foundation Trust

    London, United Kingdom · Recruiting

  • King's College Hospital NHS Foundation Trust

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.